A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Mavorixafor (Primary)
- Indications WHIM syndrome
- Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
- Sponsors X4 Pharmaceuticals
- 19 Oct 2019 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.
- 19 Oct 2019 Planned primary completion date changed from 1 Aug 2021 to 1 Sep 2021.
- 26 Jun 2019 Status changed from not yet recruiting to recruiting as per an X4 Pharmaceuticals, Inc. media release.